<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02028598</url>
  </required_header>
  <id_info>
    <org_study_id>CTC-PED-DDI-1</org_study_id>
    <nct_id>NCT02028598</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction of Clomipramine HCl and Sildenafil Citrate in Healthy Males</brief_title>
  <official_title>A Randomized, Open-labeled, 6-sequence, 3-period, 3-treatment Crossover Study to Evaluate the Effect of Co-administration of Clomipramine HCl (Condencia Tab.) 15mg and Sildenafil Citrate (Viagra Tab.) 100mg on the Safety and Pharmacokinetic/Pharmacodynamic Properties of Clomipramine and Sildenafil Compared to the Effects After Single Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CTC Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Symyoo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CTC Bio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and pharmacokinetics/pharmacodynamics of
      co-administration of Clomipramine HCl 15mg and Sildenafil citrate 100mg compared to the
      effects after single oral administration in Korean healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clomipramine is a dibenzazepine-derivative tricyclic antidepressant (TCA) and is a potent
      inhibitor of serotonin and norepinephrine reuptake. Clomipramine may be used in a variety of
      indications. Condencia Tab contains low dose of 15mg of clomipramine HCl as an active
      ingredient, which is newly approved to market for the treatment of premature ejaculation.

      This study is a prospective, randomised, open-labeled, 6-sequence, 3-period, 3-treatment,
      crossover, and single-center clinical trial. A total of 30 healthy male volunteers will be
      enrolled and randomised into one among 6 groups (5 subjects per a group). The safety and
      PK/PD characteristics of co-administration of Clomipramine HCl and Sildenafil citrate will be
      investigated closely compared to the effects after single dose administrations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The systemic exposure measured as area under the curve (AUC)</measure>
    <time_frame>From Day 1(dosing) to Day 4(72hrs)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum concentration (Cmax)</measure>
    <time_frame>From Day 1(dosing) to Day 4(72hrs)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters except the primary endpoints</measure>
    <time_frame>From Day 1(dosng) to Day 4(72hrs)</time_frame>
    <description>Including Tmax, T1/2, AUCnorm, Cmax norm, CL/f and Cmax/AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum change of systolic blood pressures within 12hrs after dosing</measure>
    <time_frame>Day 1(dosing) to Day 2(12hrs)</time_frame>
    <description>At supine and upright positions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>For 3 Weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum change of dystolic blood pressure within 12hrs after dosing</measure>
    <time_frame>From Day 1(dosing) to Day 2(12hrs)</time_frame>
    <description>at supine and upright positions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum change of heart rates within 12 hours after dosing</measure>
    <time_frame>From Day 1(dosing) to Day 2(12hrs)</time_frame>
    <description>At supine and upright positions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of the subjects who experienced the clinically significant change of blood pressures</measure>
    <time_frame>From Day 1(dosing) to Days 2(12hrs)</time_frame>
    <description>Clinically significant changes will be classified into 4 groups: SBP change &gt;=30 or 20 mmHg, DBP change &gt;= 20 or 10 mmHg (at supine and upright positions)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 1 - Treatment 2 - Treatment 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 1 - Treatment 3 - Treatment 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 2 - Treatment 1 - Treatment 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 2 - Treatment 3 - Treatment 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 3 - Treatment 1 - Treatment 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 3 - Treatment 2 - Treatment 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment 1</intervention_name>
    <description>An oral single dose administration</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_label>Sequence E</arm_group_label>
    <arm_group_label>Sequence F</arm_group_label>
    <other_name>Clomipramine HCl 15mg (Condencia Tab)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment 2</intervention_name>
    <description>An oral single dose administration</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_label>Sequence E</arm_group_label>
    <arm_group_label>Sequence F</arm_group_label>
    <other_name>Sildenafil citrate 100mg (Viagra Tab)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment 3</intervention_name>
    <description>Co-administration of oral single doses</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_label>Sequence E</arm_group_label>
    <arm_group_label>Sequence F</arm_group_label>
    <other_name>Clomipramine HCl 15mg (Condencia Tab)</other_name>
    <other_name>Sildenafil citrate 100mg (Viagra Tab)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Korean healthy males aged between 19 and 65

          -  Body weight between 60kg and 90kg, BMI between 19 and 27

          -  Given informed consent

        Exclusion Criteria:

          -  Clinically significant medical history and/or concurrent disease

          -  SBP &gt;=140 mmHg or &lt;=90 mmHg, DBP &gt;=95 mmHg or &lt;=50 mmHg

          -  Orthostatic hypotension

          -  Hypersensitivity to any ingredient of investigational drugs

          -  Severe bleeding or blood donation within 8 weeks prior to study participation

          -  Alcoholism or drug abuser

          -  Smoking more than 0.5 pack-year

          -  Persistent alcohol consumption more than 21 units(210g)/week

          -  Participation in other investigational clinical trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun Hi Kang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yangji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yangji Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <last_update_submitted>September 12, 2014</last_update_submitted>
  <last_update_submitted_qc>September 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clomipramine</keyword>
  <keyword>Premature ejaculation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Clomipramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

